Unilever’s volume rebound, the McCormick deal, and two senior sales

Unilever’s case starts with a simple fact, the business is finally getting more out of volume than it is asking from price. That matters in packaged goods, where the last few years have punished companies that leaned too hard on pricing and then had to watch shoppers trade down, push back, or simply buy less. In that context, Unilever’s H1 2026 result, 4.8% underlying sales growth, split into 4.2% volume and 0.6% price, is not cosmetic. It is the sort of mix investors in consumer staples have been waiting for.

The second-quarter print sharpened that picture. Q2 underlying sales growth accelerated to 5.8%, with 5.5% volume, the strongest quarterly volume performance in over a decade, according to the company’s results. That is the kind of number that changes how you talk about a staples name. It says the portfolio is not just defending shelf space, it is taking it back in places where the category had become a pricing exercise. Unilever also lifted full-year 2026 guidance to the 4 to 6% multi-year range, with around 3% volume growth and 4 to 5% second-half growth led by pricing, which tells you management thinks the first-half momentum can survive the usual seasonal and macro noise.

That historical cohort number is the kind of thing you use to keep your feet on the floor. It is not a forecast for Unilever, and it is not a promise that this filing pattern will work here. It is simply the historical T+90 average for the relevant role and size bucket in our data, and it sits in the background while you judge the company on its own facts.

Why the portfolio shift matters for Unilever

The strongest version of the Unilever story is not complicated. The company is pushing toward categories with better growth characteristics, it is simplifying the portfolio, and it has shown that the core brands can still generate volume in a market that has been stingy with it. The company’s Power Brands, which account for 78% of turnover, delivered above-average volume growth in H1, and that is the sort of detail that matters more than a glossy strategic slide. If the brands that actually pay the bills are growing faster than the group, the portfolio is doing some of the work for you.

The Foods separation is part of that same logic. Unilever agreed in March 2026 to combine its Foods business with McCormick, creating a combined entity with roughly $20 billion in annual revenue, and the deal remains on track for mid-2027 completion. The company also agreed to two-year employment protections for its European and UK food workforce after closing. That is not just a labor-relations footnote. It tells you management knows the transaction has to be executed without creating unnecessary friction in a business that still has to run while the paperwork, approvals, and integration planning grind on.

The planned divestment of Colman’s ahead of the separation fits the same pattern. Unilever is not trying to keep every legacy asset under one roof and hope the market gives it credit for complexity. It is pruning. That can help the market assign a cleaner multiple to the remaining consumer and personal care mix, especially if the company keeps proving that volume can carry more of the load. In a sector where investors have spent a lot of time debating whether pricing power is fading, a company that can show volume-led growth gets a better hearing.

Consumer staples still trade on execution, not slogans

The sector backdrop is better for Unilever than it was when pricing was doing all the work, but it is not easy. Consumer staples have been under pressure from softer developed-market demand, consumer pushback on price hikes, and a broader rotation into higher-growth areas such as technology. That has left the group in a strange place. It is defensive, but not automatically loved. It can attract money when the market gets nervous, but it still has to earn its keep with execution.

Peers are dealing with the same basic problem, just with different mixes. Procter & Gamble has faced similar volume and pricing challenges in recent updates, while Nestlé and Reckitt Benckiser have shown different degrees of resilience depending on category and geography. Unilever’s advantage, at least for now, is that its H1 volume trend and its portfolio shift point in the same direction. The company is leaning more into beauty, wellbeing, and personal care, and that is where investors tend to be more forgiving if the growth is real. The catch is that the market has seen enough “growth mix” stories to know that category labels do not pay the dividend by themselves.

Wider equity markets have also been rotating away from concentrated technology leadership toward more defensive areas, with geopolitical uncertainty, variable consumer confidence, and central-bank policy still in the frame. That has kept staples relevant for income and stability, even as the sector has lagged broader indices in parts of 2026. Unilever sits right in that cross-current. If the market wants defensives, it can own this name. If the market wants excitement, it will look elsewhere. That is not a flaw, but it does mean the stock often trades on whether the latest operating update feels durable enough to justify patience.

The insider sales are the part you do not ignore

Now the catch. The most recent insider record is not a buying story. Fabian Garcia, Business Group President for Personal Care, sold 15,643 ADRs on August 21 at approximately $63.92 each, for an aggregate filing value of about EUR 1 million after euro-normalisation. Heiko Schipper, Business Group President for Foods, sold 70,110 shares on July 31. Those are senior names, and they sit close enough to the operating story that you do not dismiss them as random noise.

The important thing is not to overread them either. Senior executives sell for all sorts of reasons, and the filing record alone does not tell you whether the sale was planned, routine, or tied to personal portfolio management. What it does tell you is that there is no fresh insider buying in the most recent filings to reinforce the bullish operating update. That matters because Unilever’s stock has been getting support from the business narrative, and insider buying would have been a cleaner way to show that management itself thought the market was still underestimating the setup.

Our scoring sits in the background here, not as a verdict but as a way to keep the filing in context. The pattern is not the kind that usually screams urgency. It is more restrained than that. You have a company with improving volume, a strategic simplification under way, and senior sales rather than purchases. That combination does not cancel the bull case, but it does stop you from turning the H1 numbers into a one-way story.

What the H1 numbers actually buy you

The H1 result buys Unilever credibility. It does not buy it immunity. A 4.8% underlying sales growth print, with 4.2% volume and 0.6% price, is a better mix than the market had become used to seeing from many staples names. Q2’s 5.5% volume growth is even better. But the market will want to know whether that is a one-off catch-up, a benefit from category mix, or the start of a more durable run.

That is where the company’s own guidance matters. Management’s upgrade to the 4 to 6% multi-year range, with around 3% volume growth and 4 to 5% second-half growth led by pricing, implies confidence that the first-half momentum can hold. It also implies that pricing is still part of the equation, just not the whole equation. For a staples company, that is a healthier balance than the old model of pushing price and hoping the consumer never blinks.

The market will also watch whether the Foods transaction changes how investors think about the remaining business. A cleaner portfolio can help, but only if the separation does not distract management from the core brands that are already doing the work. The company has said the deal remains on track for mid-2027 completion, which gives it time, but not much room for drift. Execution risk is not theoretical here. It is the thing that can turn a good strategic story into a long, dull process that the market stops rewarding.

The read breaks down when the risks stack up

The first risk is obvious, consumer demand can soften again. Staples companies live with the constant possibility that shoppers become more price-sensitive, especially if inflation, wages, or confidence move the wrong way. Unilever’s recent volume strength is encouraging precisely because it suggests the company is not relying only on price. But if the macro backdrop turns less friendly, the same portfolio that looks resilient today can look merely defensive tomorrow.

The second risk is that the portfolio shift takes longer than the market wants. The move toward beauty, wellbeing, and personal care is sensible, and the Foods separation is a logical part of that. Still, portfolio simplification is not a magic trick. It can take quarters, sometimes years, before the market decides the new mix deserves a better multiple. If the company spends too long in transition, the stock can end up stuck between the old business and the new one.

The third risk is that the insider pattern does not help the bull case. Two senior sales do not make a thesis, but they do make you ask whether management sees the current share price as fully reflecting the improved operating picture. You do not need to invent motive to notice the absence of buying. In a name that has just delivered its strongest quarterly volume performance in over a decade, the lack of fresh insider accumulation is a real counterweight.

The balanced verdict on Unilever now

Unilever has earned a better hearing than it had when pricing was doing too much of the talking. The H1 numbers are real, the Q2 volume print is better than the market has seen from this company in years, and the Foods separation gives the equity story a cleaner shape if management executes it properly. That is the bull case, and it is not flimsy.

The catch is that the insider record does not join the celebration. Fabian Garcia sold 15,643 ADRs on August 21, Heiko Schipper sold 70,110 shares on July 31, and the most recent filings do not show material buying. Against a backdrop where consumer staples are still fighting for attention and peers are wrestling with the same pricing and demand issues, that matters. It does not break the story. It does keep it honest.

If you want the practical read, it is this. Unilever looks better on operations than it did a few months ago, and the market has a legitimate reason to watch the portfolio shift closely. But the filing pattern says management is not leaning in with personal capital, and the cohort history in our data is not strong enough to pretend that insider sales here are a green light. The next hard checkpoint is whether the company can keep volume momentum alive into the second half while the McCormick transaction and the Colman’s divestment move forward on schedule.

This is not investment advice.